Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001378977 | SCV001576688 | likely pathogenic | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5 | 2020-05-12 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (ExAC no frequency). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CACNA1S are known to be pathogenic (PMID: 26247046, 28012042). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has not been reported in the literature in individuals with CACNA1S-related conditions. ClinVar contains an entry for this variant (Variation ID: 633680). This sequence change affects a donor splice site in intron 33 of the CACNA1S gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. |
Revvity Omics, |
RCV000782244 | SCV003822399 | likely pathogenic | not provided | 2022-09-15 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003446433 | SCV004173055 | likely pathogenic | Malignant hyperthermia, susceptibility to, 5 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003141766 | SCV004173056 | likely pathogenic | Hypokalemic periodic paralysis, type 1 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Gharavi Laboratory, |
RCV000782244 | SCV000920734 | uncertain significance | not provided | 2018-09-16 | no assertion criteria provided | research |